Comparative genomic hybridization (CGH) is a technique that has greatly facilitated detection of gains and losses in DNA copy number, and has been of particular utility in elucidating the pattern of ...

Array CGH has been implemented using a wide variety of techniques. The initial approaches used arrays with elements produced by spotting DNA obtained directly from large-insert genomic clones such as ...

Comparative genomic hybridization (CGH) was developed to identify pathogenic DNA copy-number changes (e.g., duplications, deletions) on a genome-wide scale, and to map these changes to genomic ...

Expert Rev Mol Diagn. 2012;12(3):253-264. Cytogenetics can detect clonal CNAs not identified using arrays when they occur in less than 20–30% of metaphases; Arrays cannot detect copy neutral balanced ...

Roche NimbleGen, Inc. has launched NimbleGen Comparative Genomic Hybridization (CGH) microarrays in a 12x135K format for analysis of DNA copy number variation. NimbleGen CGH 12x135K arrays will allow ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE:A) today announced that scientists using the company’s comparative genomic hybridization (CGH) technology have shown that cancer ...

Early efforts to examine genomic changes in the clinical setting relied on cytogenetic techniques such as chromosome karyotyping, a widely used approach to examine chromosomes and identify changes ...

Microarray based comparative genomic hybridisation (array CGH) is a new technology with uses developing in various diagnostic areas within the NHS. One important context is the investigation of ...

BRAF V600E mutations in benign and malignant peripheral nerve sheath tumors. Background: Gain or loss of chromosome arms are frequently detected in gastrointestinal stromal tumors (GISTs), and have ...

Agilent Technologies Inc. (NYSE: A) today announced that it was awarded a significant patent for comparative genomic hybridization methods. CGH methods help researchers study genetics and cancer in ...